The Journal of Allergy and Clinical Immunology: In Practice
Review and Feature Article“Trying, But Failing” — The Role of Inhaler Technique and Mode of Delivery in Respiratory Medication Adherence
Key words
Abbreviations used
Cited by (0)
Conflicts of interest: H. Chrystyn is on the board of and is director of Talmedica Ltd; has received consultancy fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Innovata Biomed, Meda, Napp Pharmaceuticals, Mundipharma, NorPharma, Norvartis, Orion, Sanofi, Teva, Truddell Medical International, UCB, and Zentiva; has received research support from Engineering and Physical Sciences Research Council and Medical Research Council; has received lecture fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Innovata Biomed, Meda, Napp Pharmaceuticals, Mundipharma, NorPharma, Norvartis, Orion, Sanofi, Teva, Truddell Medical International, UCB, and Zentiva; has received payment for developing educational presentations from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Innovata Biomed, Meda, Napp Pharmaceuticals, Mundipharma, NorPharma, Norvartis, Orion, Sanofi, Teva, Truddell Medical International, UCB, and Zentiva; and is owner of (with stock in) Inhalation Consultancy Ltd. S. Bosnic-Anticevich is on the Teva Devices Advisory Board; is on the Mundipharma Advisory Board; has received consultancy fees from Mundipharma; has received lecture fees from Teva, GlaxoSmithKline, and Mundipharma; and has received payment for the development of educational presentations from Teva. T. van der Molen has received consultancy fees from Boehringer Ingelheim, Teva, Mundipharma, and AstraZeneca; is employed by Universitair Medisch Centrum Goningen; has received research support from AstraZeneca and GlaxoSmithKline; has received lecture fees from Novartis, Teva, and AstraZeneca; and has received payment for developing educational presentations from Teva. R. J. Dandurand has received research support from Almiral, AstraZeneca, Boehringer Igelheim, Merck, and Novartis; has received lecture fees from Novartis; and has received payment for developing educational presentations from AstraZenenca D. Price is on the boards for Aerocrine, Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva; has received consultancy fees from Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, and Teva; has received research support from UK National Health Service, British Lung Foundation, Aerocrine, AKL Ltd, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Eli Lilly, GlaxoSmithKline, Meda, Merck, Mundipharma, Napp, Novartis, Orion, Pfizer, Respiratory Effectiveness Group, Takeda, Teva, and Zentiva; has received lecture fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, SkyePharma, Takeda, and Teva; has received payment for manuscript preparation from Mundipharma and Teva; has a patent with AKL Ltd; has received payment for developing educational presentations from GlaxoSmithKline and Novartis; has stock in AKL Ltd; has received travel support from Aerocrine, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva; has received funding for patient enrollment or completion of research from Almirall, Chiesi, Teva, and Zentiva; has served as a peer reviewer for grant committees Medical Research Council (2014), Efficacy and Mechanism Evaluation programme (2012), and Health Technology Assessment (2014); and is an 80% owner of Research in Real Life, Ltd (and its subsidiary social enterprise Optimum Patient Care), which receives unrestricted funding for investigator-initiated studies from Aerocrine, AKL Ltd, Almirall, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, Orion, Takeda, Teva, and Zentiva. The rest of the authors declare that they have no relevant conflicts of interest.